4.1 | Main findings
AHPV-GT positivity was confirmed as an independent prognostic marker for 2-year cumulative progression in the multivariate analysis (P< 0.001). After 2 years of follow-up of women with histological LSIL (CIN1) preceded by AHPV-positive/normal or mildly abnormal cytology, AHPV-GT-positive women were 3.9 times (19.0% vs. 4.8%, P < 0.001) more likely to develop CIN2+ and 5.0 times (8.6% vs. 1.7%, P = 0.014) more likely to develop CIN3+ than AHPV-GT-negative women. The 2-year CIRs of CIN3+ in AHPV-GT-positive women were significantly higher than those in AHPV-GT-negative women in the ≥25-year-old group (10.9% vs. 1.5%, P = 0.002) but slightly higher in the 21–24-year-old group (P > 0.05). These results support the value of risk stratification using AHPV-GT testing in managing women with histologic LSIL (CIN1) preceded by AHPV-positive/normal or mildly abnormal cytology.